IVADANTIN Drug Patent Profile
Which patents cover Ivadantin, and when can generic versions of Ivadantin launch?
Ivadantin is a drug marketed by Procter And Gamble and is included in one NDA.
The generic ingredient in IVADANTIN is nitrofurantoin sodium. There is one drug master file entry for this compound. Additional details are available on the nitrofurantoin sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IVADANTIN?
- What are the global sales for IVADANTIN?
- What is Average Wholesale Price for IVADANTIN?
Summary for IVADANTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Patent Applications: | 3 |
| DailyMed Link: | IVADANTIN at DailyMed |
US Patents and Regulatory Information for IVADANTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procter And Gamble | IVADANTIN | nitrofurantoin sodium | INJECTABLE;INJECTION | 012402-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
